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Background: Diseases affecting the macula, such as age-related macular degeneration
(AMD), diabetic retinopathy and central serous retinopathy can result in impaired
photostress recovery time (PSRT) despite normal visual acuity and fundoscopic appearance. The MDD-2 Macular Degeneration Detection Device is a novel flash photostress
recovery device. In this study, we examine the repeatability of the MDD-2 in a normal
population and its suitability for incorporation into routine clinical practice.
Methods: One hundred (60 female) subjects (mean age 35 ⫾ 8 years; range 18 to 66
years) were recruited to partake in this study. The photostress recovery time was measured using the MDD-2 on three occasions in the dominant eye and one final occasion
in the non-dominant eye to assess measurement repeatability. All subjects were in good
ocular health. Visual acuity and iris colour were recorded for each participant.
Results: Repeated measures analysis of variance revealed a statistically significant learning effect on intra-measurement repeatability (p < 0.01). Although paired t-test analysis
revealed statistically significant differences between repeated measures both within and
between eyes (p < 0.05 for all) the correlation between repeat measurements is statistically significant (p < 0.05 for all), and the coefficient of repeatability reaches clinically
acceptable levels once the initial photostress recovery time, which demonstrated
increased variability and latency compared to all subsequent measures, is excluded.
Conclusion: The MDD-2 provides highly repeatable measurements of photostress
recovery time among young naïve subjects, following verbal explanation of the task and
only one ‘practise’ measurement. The measurement is also highly repeatable between
eyes, providing a potential immediate clinical biomarker of ocular health.

Key words: age-related macular degeneration, macula, MDD-2, photostress recovery time

Early detection of visual loss, such as is
associated with macular disease, including age-related macular degeneration
(AMD), diabetic retinopathy and central
serous retinopathy, is of prime concern
to eye-care practitioners and health-care

providers for a number of reasons, which
include:
1. the increasing prevalence of ocular
disease1–3
2. the likely increase in consequential
visual impairment and blindness4,5

© 2012 The Authors
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3. the possibilities for retarding disease
progression through supplementation6
and
4. recent advances in pharmacologic
management of conditions, such as
AMD, which are best applied at the
Clinical and Experimental Optometry 2012
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earliest stages of the development of
abnormal pathology.7
In addition, it is also important that
functional biomarkers provide prognostic
information and guide clinical decisions
around the need for treatment and its
success.8,9
Although visual acuity (VA) alone is
an inadequate marker of visual function
in macular disease,9 other biomarkers
including photopic and scotopic light
sensitivity,10 flicker sensitivity,11 colour
vision,12 contrast sensitivity,13 dark adaptation14,15 and photostress recovery16 can
provide additional capacity to detect the
early signs of retinal degeneration. It has
been suggested that these early signs are
partially attributable to an increased effect
of intraocular scattered light in the diseased eye,17–19 along with excessive photoreceptor bleaching due to the relative
lack of photo-protection in the affected
retina. In particular, photostress recovery
time (PSRT) has been shown to be
adversely affected by retinal and macular
disease.16,20,21
Photostress recovery time describes the
time required to regain normal visual
function after viewing a light source so
intense as to bleach the visual pigments
and saturate the response of the macular
photoreceptors, and therefore cause transitory loss of vision.22,23 This dynamic
assessment of macular function, originally
described for the assessment of central
serous retinopathy24 is an excellent indicator of retinal integrity, as normal recovery
depends on an efficient and intact underlying retinal photoreceptor and pigment
epithelial function.25,26 Therefore, it can
be used to indentify insidious, pre-clinical
macular disease and potentially in
advance of a reduction in VA, a defect on
Amsler grid27 or other clinical manifestations. A recent evaluation of potential
biomarkers of early AMD found that PSRT
achieved high diagnostic capacity and provided the optimal qualitative assessment of
visual function in early AMD.16 Abnormal
PSRTs may also be used to differentiate
retinal/macular from neural/optic nerve
disease.27,28
Macular photostress can be induced
either using a brief flash of intense light
Clinical and Experimental Optometry 2012
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delivered to the macula or using a more
sustained and lower-intensity light source
such as the ophthalmoscope. Flash recovery testing is effective in the detection
of early macular disease.29 The MDD-2
Macular Degeneration Detection Device is
a novel flash photostress recovery device.
This device is capable of detecting functional visual loss in AMD and diabetic
maculopathy.20 No previous study has
explored the clinical applicability of this
test in terms of learning and repeatability.
In this study, we examine the repeatability
of the MDD-2 in a normal population
and its suitability for incorporation into
routine clinical practice.

METHODS
One hundred subjects (60 female) participated in this study (one additional subject
was excluded on the basis of the presence
of ocular pathology), which was approved
by the Research Ethics Committee at
Dublin Institute of Technology (DIT).
Informed consent was obtained from each
volunteer and the experimental procedures adhered to the tenets of the Declaration of Helsinki.
The study was conducted in the Vision
Science Laboratory and National Optometry Centre at DIT. Recruitment of subjects was by word of mouth. All subjects
were aged between 18 and 66 years, in
good general (by self-report) and ocular
(determined by ophthalmoscopy) health
and with logMAR visual acuity of at least
0.2 (6/9) in the study eye. Exclusion criteria included any sign of retinal or ocular
abnormality, any known systemic health
condition and logMAR visual acuity less
than 0.2. A computer-generated logMAR
test chart (Thomson 2000 Pro; Thomson
Software Solutions, Hatfield, United
Kingdom) was used to determine logMAR
acuity. Iris colour was recorded using an
iris colour classification scheme, with iris
colour matched to standard colour photographs and classified into one of five categories (grey, blue, green, light brown,
brown) as described by Seddon.30 All subjects recruited into the study were naïve to
the MDD-2 test.

Photostress recovery time was measured
using the MDD-2 Macular Degeneration
Detection Device. The MDD-2 is a relatively simple device, comprising a spectrally broadband xenon flash light source
with good short- (around one per cent)
and long-term (around three per cent)
output stability, a UV and IR filter and
focussing (+8.00 D) lens. The test involves
accurate identification (post-flash photostress) of a large (0.41 radian or 23.5°)
angular subtense and stroke width of
about 2.7°, requiring about 6/120 Snellen
acuity (logMAR 1.3), internally presented
and randomly generated numbers
between zero and nine. The target is
viewed through a 12 mm central aperture
in the flash tube. The 200 msec duration
flash is generated by a xenon flash source
(mouser type FT04050), mounted inside
the flash tube within the subject’s field of
view (flash source to cornea distance
of approximately 50 cm) and generates
uniform maximum irradiance of 4.5
W/cm2 at the viewing aperture across an
angular subtense of 0.67 radians (38.4°).
The nature of the test and stimuli were
described in detail to each subject and the
subjects were requested to confirm their
understanding of the task. The test was
conducted using natural, undilated pupils
in ambient room lighting conditions averaging 870 lux. The flash tube was positioned against the test eye and the subject
was required to correctly identify a baseline, pre-photostress, numeric stimulus
without their refractive correction. Subjects were instructed to stare into the
device at the instant they were ready to
begin the test, to fixate centrally at the
position of the pre-bleach stimulus and to
avoid blinking at the onset of the photostress flash. When ready to commence the
test proper, the subject pressed a button
on the device, which initiated three concurrent processes; the arc flash photostress, the photostress recovery timer and a
new random number display. Once vision
recovered sufficiently to allow number
recognition, the subject was required to
verbally identify the new number and
simultaneously, to press the same button
on the device to cease the test. The actual
number presented by the device and the
© 2012 The Authors
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The mean age (⫾ SD) of the sample was
35 ⫾ 8 years and ranged from 18 to 66
years. The mean VA was logMAR -0.04 ⫾
0.06. The mean PSRT for each of the three
measurements in the dominant eye and
the final measurement in the fellow eye
are presented in Table 1. They demonstrate a trend toward improved PSRT with
each sequential measurement in the

Photostress measurement (eye)

Mean ⫾ SD PSRT (seconds)

Range (seconds)

7.37 ⫾ 3.2

3–24

PSRT 1 (Dominant)
PSRT 2 (Dominant)

5.50 ⫾ 1.70

3–10

PSRT 3 (Dominant)

5.11 ⫾ 1.51

3–11

PSRT 4 (Non-dominant)

5.83 ⫾ 1.72

1–12

SD = standard deviation

Table 1. Mean photostress recovery times (PSRT) for the first (PSRT 1), second (PSRT
2) and third (PSRT 3) measurements of the dominant eye of participants and mean
PSRT of the non-dominant eye (PSRT 4).

A

B
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PSRT 2 Dominant (secs)

45
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subject’s PSRT were vocally confirmed by
the device, allowing the examiner to determine the accuracy of the subject response
and to record the PSRT. Three successive
measurements (PSRT 1, PSRT 2 and PSRT
3), separated by two-minute intervals
(determined as a sufficient time interval to
allow retinal recovery during a pilot study)
were recorded for the subject’s dominant
eye (determined using the Miles Test).31
One further reading was taken using the
non-dominant eye (PSRT 4). Incorrect
identification of the test stimulus at baseline resulted in exclusion from the study.
A single incorrect response during the test
phase was permitted (result discarded and
test repeated following a two-minute interval) but a second incorrect response
resulted in exclusion from the study.
The statistical software package SPSS
(version 18) was used for analysis (SPSS
Inc., Chicago, IL, US). A linear regression
analysis was used to assess for an effect of
age, sex and iris colour on photostress
times. Pearson correlation coefficients
were calculated to investigate the relationship between sequential measurements
and between eyes. Bland–Altman analysis
and plots, as well as the limits of agreement, were used to quantify the agreement between repeat measures of the
PSRT. Intra-measurement repeatability is
expressed as a coefficient of repeatability,
which was calculated as the standard
deviation of the mean difference between
measurements and multiplied by 1.96.
Repeated measures analysis of variance
(ANOVA) was conducted to test for a
learning or fatigue effect that might confound the test-retest analysis. A five per
cent significance level was used throughout the analysis.

PSRT 2 Dominant (secs)

1
23

6

4

2

6

4

2

y = 0.587x + 1.880

y = 0.412x + 3.014

2

R2 = 0.286

R = 0.438
0

0
0

10

20

PSRT 3 Dominant (secs)

0

10

20

PSRT 4 Non-dominant (secs)

Figure 1. Correlation between (A) photostress recovery time for the second (PSRT 2)
and third (PSRT 3) measurements of the dominant eye and (B) photostress recovery
time for the second (PSRT 2) measurement of the dominant eye and the first measurement of the non-dominant eye (PSRT 4)

dominant eye, with the most substantial
improvement in PSRT occurring between
PSRT 1 and PSRT 2.
Repeated measures ANOVA, using a
general linear model approach, with
age, sex and iris colour as co-variates,
confirmed the presence of an intra-

© 2012 The Authors
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measurement learning effect (p < 0.001),
as demonstrated by a gradual shortening
of successive PSRT measures in the dominant eye. Pearson’s correlation revealed
a moderate and significant relationship
between PSRT 2 and PSRT 3 in the dominant eye (r = 0.66; p < 0.01; Figure 1a) and
Clinical and Experimental Optometry 2012
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Figure 2. Bland–Altman plot showing 95 per cent limits of
agreement for repeat measurements in the dominant eye (PSRT
2 and PSRT 3)
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Figure 3. Bland–Altman plot showing 95 per cent limits of
agreement for repeat measurements between eyes (PSRT 2 and
PSRT 4)
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a similarly significant inter-eye correlation
(r = 0.58; p < 0.01; Figure 1b), indicating
good within- and between-eye associations
for repeated measures.
Bland–Altman analysis and plots were
used to assess intra- and inter-eye agreement. The difference in mean recovery
time between PSRT 2 and PSRT 3 in the
dominant eye (0.39 seconds) and limits of
agreement are presented in Figure 2. A
paired t-test revealed a significant difference in PSRT between repeat measures of
the same eye (t = 2.93, p = 0.004), indicating a bias toward shorter recovery times in
PSRT 3. The coefficient of repeatability in
the dominant eye was 2.61 seconds and for
76 per cent of subjects, the difference in
recovery time between PSRT 2 and PSRT 3
was one second or less, indicating good
within-eye repeatability. When comparing
both PSRT 2 and PSRT 3 with PSRT 1, the
coefficients of repeatability were significantly poorer at 4.69 seconds (PSRT 2)
and 5.67 seconds (PSRT 3), respectively.
In addition, differences between recorded
recovery times were one second or less for
only 49 per cent (PSRT 1 versus PSRT 2)
and 37 per cent (PSRT 1 versus PSRT 3) of
subjects, indicating poorer repeatability,
when using the initial PSRT 1 as the baseline value.
Clinical and Experimental Optometry 2012
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The inter-eye difference between mean
PSRT 2 and PSRT 4 (0.33 seconds) and
limits of agreement are presented in
Figure 3. A paired t-test revealed a significant difference in PSRT between eyes (t =
2.24, p = 0.028), indicating a bias toward
longer recovery times in the fellow, nondominant eye. The coefficient of repeatability for between eye measurements was
3.19 seconds and 67 per cent of subjects
exhibited an inter-eye difference of one
second or less, indicating good repeatability between eyes.
DISCUSSION
Although available evidence suggests that
PSRT is sensitive to diseases like early
AMD, it is little used in clinical practice.
Despite its clinical simplicity and ability to
detect worsening pathology even before
ophthalmoscopic manifestations,27 the
macular photostress recovery test has not
been widely used by clinicians for several
reasons, typically due to the inherent
variability of previous tests (for example,
providing a single standard for an
ophthalmoscopy-based technique would
be almost impossible as the expected
degree of photostress would vary with
battery charge level, light bulb type and

letter chart variability),32 as well as difficulty implementing such tests into routine
clinical practice (for example, the use of a
perimeter to measure the recovery of sensitivity following photostress still requires
an additional photostress source or
alternatively, a non-standard perimetric
routine).28
A legitimate criticism of the PSRT
concept is the lack of any standardised test
for the PSRT or clinical guidelines for
implementation and interpretation, which
can be used to reliably and efficiently
provide an indicator of functional visual
status and its relation to retinal and
macular disease and perhaps to cataracts.33 Numerous devices including the
Scotometer,34 the Brightness Acuity Test
(BAT)35 and the Eger Macular Stressometer36 have been developed but not
adopted for routine clinical practice.
Device adaptations have also been used to
provide a PSRT, using instruments such as
the ophthalmoscope,32 the electroretinogram25 and the automated perimeter.28 No
device or technique has proved capable
of providing a clinically acceptable gold
standard measure of PSRT that is widely
applicable and acceptable to routine clinical practice. The current results advance
the possibility that the MDD-2 could
© 2012 The Authors

Clinical and Experimental Optometry © 2012 Optometrists Association Australia

42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72

JOBNAME: No Job Name PAGE: 5 SESS: 11 OUTPUT: Fri Oct 5 17:38:07 2012
/v2503/blackwell/journals/cxo_v0_i0/cxo_813

MDD-2 photostress recovery time Loughman, Hewitt, Judge, Martin, Moulds and Davison

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

provide such a measure, although it
remains premature to definitively conclude this.
The current study was designed to evaluate the repeatability of the MDD-2 within a
single clinical session to determine:
1. whether a substantial practise session
would be required before a reliable
and repeatable baseline measure of
PSRT could be determined among
naïve subjects and
2. the degree of inter-eye symmetry that
might be expected among normal subjects, which could provide an indication of the capacity of the device to
detect unilateral or asymmetric bilateral pathology, such as central serous
retinopathy or AMD (as an asymmetric
PSRT) at a single visit.
Although the device is marketed as an
AMD detection tool, it is likely that optometrists and eye-care practitioners would
use the device routinely for ‘normal’
patients, both as an added ocular health
check and as part of any preventive health
or screening strategy for AMD. Therefore,
it is essential that the device is first tested
for repeatability and ease of use among a
normal population, which represents the
aim of the current study.
Statistical analysis reveals a significant
learning effect and difference between
repeat measures of PSRT both within and
between eyes. The significance of these
differences is of clinical relevance only for
the PSRT 1 measurement, which is considerably more variable (the standard deviation and range of PSRT measures are two
to three times larger than in any of the
three subsequent measurements), and
considerably slower (up to 44.2 per cent
slower on average) than subsequent measures. The small variations observed among
PSRT 2, PSRT 3 and PSRT 4 are certainly
not clinically significant relative to the dramatically increased PSRT observed previously in patients with AMD or diabetic
maculopathy compared to normal controls using the same device.20
Typically it might be expected that
repeat testing at short two-minute intervals
would cause further bleaching of photopigment and consequential delays in
PSRT in normal, but particularly, in dis-

eased retinae. The observation here that
PSRT remains stable in normal eyes,
despite such short repeat test intervals is of
interest and may offer further diagnostic
potential. The typical PSRT observed is so
short and the repeat test values so stable
that it is not unreasonable to speculate
that the device might predominantly test
neural recovery mechanisms rather than
the mechanics of photopigment bleaching
and recovery. Perhaps this could be considered a ‘flash’ variation of traditional
nyctometric techniques, which evaluate
the initial two minutes of macular recovery
dynamics in response to sustained exposure to a bright light source.38
It has been shown previously that the
dynamics of short-term macular recovery
are impaired in diabetic retinopathy.38,39
Therefore, it is plausible to suggest that
short interval repeat testing could itself
reveal early retinal and macular functional
loss. This would manifest as deterioration
in PSRT, compared to the initial PSRT
measurement, on repeated short interval
testing not seen in normal observers here.
Of course, this is purely speculative at this
stage but might represent a useful further
investigation into the clinical applicability
of the MDD-2 device. This device also
appears to be robust to the possible effects
of age or iris colour on PSRT within
this sample population. Iris colour, for
example, might be expected to influence
PSRT, as relatively more light would pass
through a light compared to a dark iris.37
It appears that the small amount of light
that could traverse the lightest of irides
does not play a role in determining PSRT.
These combined results suggest that a
single practise measurement is sufficient
to overcome any learning effect. Furthermore, the degree of inter-eye symmetry
observed suggests the MDD-2 may have
the capacity to detect unilateral or asymmetric pathology, as a delayed PSRT in
one eye. The capacity of a device to
provide repeatable measurements does
not provide absolute evidence that such a
device can differentiate normal from diseased eyes. For example, the Eger Macular
Stressometer is incapable of providing
information regarding AMD severity or
progression.36 The MDD-2 is capable20 of:

© 2012 The Authors
Clinical and Experimental Optometry © 2012 Optometrists Association Australia

1. differentiating normal from AMDaffected eyes (PSRT doubled on
average in early AMD)
2. differentiating early and late forms of
AMD (PSRT doubled on average in late
compared to early stages) and
3. detecting disease progression (in
AMD and diabetic maculopathy) in the
absence of other clinical signs of deterioration of visual acuity and Amsler
grid findings.
These findings suggest that the MDD-2
is sensitive to subtle changes in macular
health, despite the test design, which
would not seem appropriate for the isolation of specific macular function (the
target and photostress areas extend significantly beyond the macula). Such design
features could prove advantageous by
extending the usefulness of the device for
non-macular disease, which may impact
PSRT, such as cataract or glaucoma,
although this concept remains to be
tested).
Therefore, it appears that an instrument based on the principles of the
MDD-2 provides a reliable and userfriendly means to assess ocular health in
routine practice. The test is easily understood and consequently requires only a
verbal description of the task, followed by
a single practise demonstration in one eye,
for naïve users to reach a learning plateau
and provide repeatable measures of PSRT.
Given the statistical significance of the
differences in repeat measures between
eyes, it would seem prudent to include a
practise measurement routinely in each
eye before valid clinical measures are
recorded. Such valid measures will serve as
the baseline for serial measurements of
PSRT. The results of the current study
suggest that deterioration of greater
than three seconds in measurements
of photostress recovery over time should
be regarded as somewhat suspicious,
although this concept warrants further
detailed and longitudinal studies.
The results cannot be generalised to a
specifically older population, which might
exhibit relatively slower normal PSRT20
and more variability in PSRT due conditions such as age-related cataracts.33 As
such, the repeatability of the test among
Clinical and Experimental Optometry 2012
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an older population more likely affected
by AMD would require additional investigation. Furthermore, the device has yet to
be proven capable of detecting the earliest
signs of disease or to detect changes in
PSRT within individuals over time as a
consequence of disease.
Although the MDD-2 device has been
designed and marketed as an AMD tool,
the current study suggests that it would
be of clinical value to incorporate this
test into routine clinical practice for all
patients. The simplicity, short duration
and diagnostic capacity of the test further
enhance the concept that it could become
an important and routinely-used clinical
test of functional macular and central
retinal integrity that can readily provide
a clinical biomarker of ocular health,
disease progression and disease severity.
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